Effects of PEG in patients with esophageal squamous cell carcinoma during concurrent chemoradiotherapy: a prospective study

被引:2
|
作者
Dong, Jie [1 ]
Dai, Zhenbo [2 ]
Cao, Fuliang [2 ]
Zhang, Wencheng [3 ]
Zhang, Tian [3 ]
Chen, Xi [3 ]
Chen, Yajun [1 ]
Zhao, Fangdong [3 ]
Li, Jiacheng [3 ]
Du, Qingwu [3 ]
Zhang, Kunning [3 ]
Zeng, Yaqi [1 ]
Li, Chunlei [1 ]
Wang, Yujie [1 ]
Li, Yueying [1 ]
Wang, Kun [1 ]
Pang, Qingsong [3 ,4 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Nutr Therapy, Tianjin, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Endoscopy Diag & Therapy, Tianjin, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Dept Radiat Oncol, Tianjin, Peoples R China
[4] Tianjin Med Univ Canc Inst & Hosp, Dept Radiat Oncol, Huanhu West Rd, Tianjin, Peoples R China
基金
中国国家自然科学基金;
关键词
PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; QUALITY-OF-LIFE; NECK-CANCER; ENTERAL NUTRITION; NASOGASTRIC TUBES; ESPEN GUIDELINES; HEAD; IMPACT; OBESITY; MALNUTRITION;
D O I
10.1016/j.gie.2023.04.2094
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims: This prospective study aimed to compare the changes in nutritional status and adverse events among patients with esophageal squamous cell carcinoma who received enteral nutrition through oral intake, PEG, and an enteral nasogastric tube (NGT) during concurrent chemoradiotherapy (CCRT). Methods: Of 141 included patients, 38, 74, and 29 patients were fed through oral intake, PEG, and NGTs, respectively. The clinical characteristics and baseline nutritional status of the 3 groups were recorded and analyzed. The Patient-Generated Subjective Global Assessment score, skeletal muscle index, and quality of life were evaluated before and after CCRT; the incidence of adverse events during feeding using PEG and NGTs was also recorded. The correlations among the different nutritional pathways and the CCRT-related adverse events (eg, radiation esophagitis and myelosuppression) were assessed. Results: At baseline, the oral intake group had a significantly better nutritional status and lower disease stage than those in the PEG and NGT groups. However, during CCRT, the oral intake group exhibited the most significant decreases in weight and skeletal muscle index. The synchronous chemotherapy completion rate was the highest in the PEG group. Multivariate analysis showed that the planning tumor volume and oral intake and NGT feeding pathways were associated with radiation esophagitis of at least grade 2. Conclusions: We found that PEG effectively maintained the body weight and skeletal muscle index of patients with esophageal cancer during CCRT. PEG also improved the synchronous chemotherapy completion rate and reduced the occurrence of at least grade 2 radiation esophagitis.
引用
收藏
页码:901 / +
页数:13
相关论文
共 50 条
  • [21] Consolidative chemotherapy after definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients: a population based cohort study
    Lin, Chen-Yuan
    Lien, Ming-Yu
    Chen, Chi-Ching
    Fang, Hsin-Yuan
    Lin, Yu-Sen
    Chen, Chien-Kuang
    Chen, Jian-Xun
    Lu, Ting-Yu
    Huang, Tzu-Min
    Hsieh, Te-Chun
    Sun, Shung-Shung
    Li, Chia-Chin
    Chien, Chun-Ru
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [22] Consolidative chemotherapy after definitive concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients: a population based cohort study
    Chen-Yuan Lin
    Ming-Yu Lien
    Chi-Ching Chen
    Hsin-Yuan Fang
    Yu-Sen Lin
    Chien-Kuang Chen
    Jian-Xun Chen
    Ting-Yu Lu
    Tzu-Min Huang
    Te-Chun Hsieh
    Shung-Shung Sun
    Chia-Chin Li
    Chun-Ru Chien
    BMC Gastroenterology, 22
  • [23] Long-term Clinical Results of Concurrent Chemoradiotherapy for Patients with Cervical Esophageal Squamous Cell Carcinoma
    Kumabe, Atsuhiro
    Zenda, Sadatomo
    Motegi, Atsushi
    Onozawa, Masakatsu
    Nakamura, Naoki
    Kojima, Takashi
    Daiko, Hiroyuki
    Shigematsu, Naoyuki
    Akimoto, Tetsuo
    ANTICANCER RESEARCH, 2017, 37 (09) : 5039 - 5044
  • [24] Definitive concurrent chemoradiotherapy with S-1 and cisplatin in elderly esophageal squamous cell carcinoma patients
    Wang, Hongqing
    Li, Gang
    Chen, Lifang
    Duan, Yuxia
    Zou, Chunpeng
    Hu, Chunhong
    JOURNAL OF THORACIC DISEASE, 2017, 9 (03) : 646 - 654
  • [25] Comparison of the Clinical Outcomes of Esophagectomy and Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma
    Lee, Myung Hun
    Park, Moo In
    Lee, Ju Won
    Jung, Kyoungwon
    Kim, Jae Hyun
    Kim, Sung Eun
    Moon, Won
    Park, Seun Ja
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2024, 83 (03): : 102 - 110
  • [26] A prospective clinical trial of camrelizumab in combination with chemoradiotherapy in patients with metastatic esophageal squamous cell carcinoma
    Chen, Yongshun
    Zhao, Wensi
    Zuo, Zhigang
    Ke, Shaobo
    Shi, Wei
    Li, Bin
    Qiu, Hu
    Wang, Jing
    Gong, Yi
    Cai, Xiaojun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [27] Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of the Rectum
    Jeong, Bae Gwon
    Kim, Dae Yong
    Kim, Sun Young
    HEPATO-GASTROENTEROLOGY, 2013, 60 (123) : 512 - 516
  • [28] A prospective study of camrelizumab monotherapy following definitive concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell cancer
    Wang, J.
    Cheng, Y.
    Wu, Y.
    Cao, F.
    Liu, Q.
    Gao, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S838 - S838
  • [29] Single-AgentVersusDouble-AgentChemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter PhaseIIClinical Trial
    Zhao, Zhenhuan
    Wen, Yixue
    Liao, Dongbiao
    Miao, Jidong
    Gui, Yan
    Cai, Hongwei
    Chen, Yang
    Wei, Min
    Jia, Qiang
    Tian, Honggang
    Sun, Mingqiang
    Zhang, Yu
    Feng, Gang
    Du, Xiaobo
    ONCOLOGIST, 2020, 25 (12): : E1900 - E1908
  • [30] RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma
    Yu, Rong
    Wang, Wenqing
    Li, Tao
    Li, Jiancheng
    Zhao, Kuaile
    Wang, Weihu
    Liang, Long
    Wu, Haishan
    Ai, Tashan
    Huang, Wei
    Li, Liyun
    Yu, Wentao
    Wei, Chenlu
    Wang, Yidi
    Shen, Wei
    Xiao, Zefen
    FUTURE ONCOLOGY, 2021, 17 (31) : 4081 - 4089